The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Crunch time approaches for UroGen.
Minghui’s MHB088C will soon start phase 3 in China.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.